RPL5 and Miyoshi myopathy: In addition, RPL5 mRNA expression level was proposed as a clinical biomarker for response to bortezomib in MM patients; Hofman et al. [28] reported significantly lower RPL5 mRNA expression in patients with MM who initially responded to bortezomib and then relapsed, and both newly diagnosed and relapsed patients with low RPL5 expression had better PFS when bortezomib was used in their treatment.